CoChat

The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma

Open access

The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.

Abstract

Glioblastoma (GBM) is the most lethal type of primary brain cancer. Standard care using chemo- and radio-therapy modestly increases the overall survival of patients; however, recurrence is inevitable, due to treatment resistance and lack of response to targeted therapies. GBM therapy resistance has been attributed to several extrinsic and intrinsic factors which affect the dynamics of tumor evolution and physiology thus creating clinical challenges. Tumor-intrinsic factors such as tumor heterogeneity, hypermutation, altered metabolomics and oncologically activated alternative splicing pathways change the tumor landscape to facilitate therapy failure and tumor progression. Moreover, tumor-extrinsic factors such as hypoxia and an immune-suppressive tumor microenvironment (TME) are the chief causes of immunotherapy failure in GBM. Amid the success of immunotherapy in other cancers, GBM has occurred as a model of resistance, thus focusing current efforts on not only alleviating the immunotolerance but also evading the escape mechanisms of tumor cells to therapy, caused by inter- and intra-tumoral heterogeneity. Here we review the various mechanisms of therapy resistance in GBM, caused by the continuously evolving tumor dynamics as well as the complex TME, which cumulatively contribute to GBM malignancy and therapy failure; in an attempt to understand and identify effective therapies for recurrent GBM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells10030484

Cites

157 of 157 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Different transcritptional subtypes of GBM cells and their associated mutations in bold. scRNA seq studies have elucidated three different subtypes of GBM cells namely Proneural (PN), Classical (CL), and Mesenchymal (MES) subtypes manifesting the PDFRA, EGFR and NF1 mutations respectively.
Figure 1 Different transcritptional subtypes of GBM cells and their associated mutations in bold. scRNA seq studies have elucidated three different subtypes of GBM cells namely Proneural (PN), Classical (CL), and Mesenchymal (MES) subtypes manifesting the PDFRA, EGFR and NF1 mutations respectively.CC BY · PubMed Central
Figure 2 Splicing can be modulated at multiple levels. Pre-splicing, modifying enzymes, like the methyltransferase PRMT5, can be inhibited preventing spliceosome assembly. Core spliceosome components, like SF3B1, can also be inhibited leading to unproductive splicing. Isoform modulation can also be a target of alternative splicing to switch to a less oncogenic protein isoform. Clinicaltrials.gov identifiers (NCT) are included where small molecule inhibitors or modulators are being tested in humans.
Figure 2 Splicing can be modulated at multiple levels. Pre-splicing, modifying enzymes, like the methyltransferase PRMT5, can be inhibited preventing spliceosome assembly. Core spliceosome components, like SF3B1, can also be inhibited leading to unproductive splicing. Isoform modulation can also be a target of alternative splicing to switch to a less oncogenic protein isoform. Clinicaltrials.gov identifiers (NCT) are included where small molecule inhibitors or modulators are being tested in humans.CC BY · PubMed Central
Figure 3 Complex pathways underlie the therapeutic resistance of GBM. The decrease of oxygen within in the tumor can facilitate hypoxia-induced signaling which can render cells less sensitive to treatment. Tumor heterogeneity can complicate therapeutic response as not all clones are targeted equally by standard treatments. Immune regulation is severely dampened in GBM, creating a “cold” TME. Splicing changes via RBPs or splicing factors can affect isoform outcome leading to dysregulated AS. Metabolic changes induced by TMZ or RT are able to change metabolism in both the tumor cells as well as the TME, creating a therapeutic-resistant microenvironment. TMZ-induced hypermutation can create a hypermutator state in which patient outcome is correlated with a worse overall survival, as compared to other cancers. Overall, many pathways play a role in GBM therapeutic resistance, and all should be investigated for better second-line treatments. RBPs, RNA binding proteins; AS, Alternative splicing; RBCs, red blood cells, CAFs, cancer-associated fibroblasts.
Figure 3 Complex pathways underlie the therapeutic resistance of GBM. The decrease of oxygen within in the tumor can facilitate hypoxia-induced signaling which can render cells less sensitive to treatment. Tumor heterogeneity can complicate therapeutic response as not all clones are targeted equally by standard treatments. Immune regulation is severely dampened in GBM, creating a “cold” TME. Splicing changes via RBPs or splicing factors can affect isoform outcome leading to dysregulated AS. Metabolic changes induced by TMZ or RT are able to change metabolism in both the tumor cells as well as the TME, creating a therapeutic-resistant microenvironment. TMZ-induced hypermutation can create a hypermutator state in which patient outcome is correlated with a worse overall survival, as compared to other cancers. Overall, many pathways play a role in GBM therapeutic resistance, and all should be investigated for better second-line treatments. RBPs, RNA binding proteins; AS, Alternative splicing; RBCs, red blood cells, CAFs, cancer-associated fibroblasts.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 157 references

Cited by

Items 101–179 of 179

Metadata

Authors
Goenka, A., Tiek, D., Song, X., Huang, T., Hu, B., & Cheng, S.-Y.
Affiliations
Northwestern University (US)
Corresponding author
Cheng, Shi-Yuan
Venue
Cells
Publisher
MDPI AG
Published
2021-02-24
Volume
10
Issue
3
Pages
484
ISSN
2073-4409 (ISSN-L)
OpenAlex
W3132558808
Cited by
169
References
157
Citations by year
2026: 30 · 2025: 40 · 2024: 27 · 2023: 36 · 2022: 26 · 2021: 10
FWCI
3.56
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Cancer Institute (CA221747, CA234799)
  • National Institute of Neurological Disorders and Stroke (NS093843, NS095634, NS115403)
  • The Lou and Jean Malnati Brain Tumor Institute at Northwestern Medcine (10031379)
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords
glioblastoma, treatment resistance, tumor recurrence, tumor heterogeneity, hypermutation, cancer metabolomics, alternative splicing, hypoxia, tumor microenvironment, immunosuppression, immunotherapy resistance, tumor evolution
MeSH terms
Brain Neoplasms, Glioblastoma, Humans, Neoplasm Recurrence, Local, Drug Resistance, Neoplasm, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.